

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. -10. (Canceled)

11. (Currently Amended) A method for treating a mammary gland disorder, the method comprising the step of local administration of between about  $10^{-2}$ U/kg and about 200 U/kg of a botulinum toxin type A to a mammary gland of a human patient to treat or cause the regression or remission of atypical tissue, thereby treating a mammary gland disorder by reducing a secretion from atypical tissue of the mammary gland.

12.-33. (Cancelled)

34. (Previously presented) A method for treating a mammary gland disorder selected from the group consisting of a breast cyst, sclerosing adenosis, duct papilloma, fibroadenoma, blunt duct adenosis, and proliferative breast disease, the method comprising the step of local administration of between about  $10^{-2}$ U/kg and about 200 U/kg of a botulinum toxin type A to a mammary gland, thereby treating the mammary gland disorder.

35. (Currently amended) The method of claim [[12]] 11, wherein the mammary gland disorder is associated with hyperplastic hyperplastic or neoplastic mammary gland cells.

36. (Previously presented) The method of claim 11, wherein said atypical tissue comprises hyperplastic tissue, a cyst, or a neoplasm.

37. (Previously presented) The method of claim 11, wherein said local administration comprises between about  $10^{-1}$  U/kg and about 35 U/kg of a botulinum toxin type A.
38. (Previously presented) The method of claim 11, wherein said local administration comprises direct injection of botulinum toxin into said atypical tissue.
39. (Previously presented) The method of claim 11, wherein said local administration comprises implantation of a botulinum toxin implant onto or into said atypical tissue.
40. (Previously presented) The method of claim 11, wherein the diameter of said atypical tissue is reduced by about 20% to about 100% subsequent to said local administration.
41. (Previously presented) The method of claim 34, wherein said local administration comprises between about  $10^{-1}$  U/kg and about 35 U/kg of a botulinum toxin type A.
42. (Previously presented) The method of claim 34, wherein said local administration comprises direct injection of botulinum toxin into said breast cyst, sclerosing adenosis, duct papilloma, fibroadenoma, blunt duct adenosis, or proliferative breast disease.
43. (Previously presented) The method of claim 34, wherein said local administration comprises implantation of a botulinum toxin implant onto or into said breast cyst, sclerosing adenosis, duct papilloma, fibroadenoma, blunt duct adenosis, or proliferative breast disease.

44. (Previously presented) The method of claim 34, wherein the diameter of said breast cyst, sclerosing adenosis, duct papilloma, fibroadenoma, blunt duct adenosis, and proliferative breast disease is reduced by about 20% to about 100% subsequent to said local administration.